Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Accurate for omeprazole’s acid suppression mechanism and the label-supported concept that gastric pH can affect absorption (including iron and some antibiotics). However, several broad or speculative interaction/compatibility and timing/management claims are not supported by the provided prescribing-information sections, and the claim set does not cover important safety label areas (e.g., boxed warnings/contraindications/pregnancy/other warnings).
Category Scores
Accurate Statements
Omeprazole lowers stomach acid.
12.1 (blocks final step of acid production via inhibition of H+/K+ ATPase)
Omeprazole mainly affects drugs whose absorption depends on an acidic stomach environment for dissolution or absorption.
7 (theoretically possible interference where gastric pH is an important determinant; includes iron salts)
Some antibiotics may have absorption changes with acid suppression.
7 (examples given include ampicillin esters; theoretical possible interference with absorption where gastric pH is important)
Medicines that require stomach acid for best absorption are likely to interact with omeprazole.
7 (theoretically possible interference when gastric pH is important for bioavailability)
Omeprazole can raise stomach pH.
12.3 (combination therapy scenario shows increased mean 24-hour gastric pH) and 7 (acid suppression basis for pH effect)
Iron products may absorb less efficiently when stomach acid is reduced.
7 (theoretically possible interference; explicitly includes iron salts)
Omeprazole is often given once daily and taken before a meal if prescribed for routine acid control.
5 (should be taken before eating) and 12.2 (inhibition increases with repeated once-daily dosing)
Omeprazole is used in children (supports pediatric GERD treatment and dosing/indication context).
8.4 Pediatric Use (GERD treatment safety/effectiveness supported) and 2.7 Pediatric Patients (pediatric dosing for GERD/maintenance of erosive esophagitis healing)
Raising stomach pH may reduce absorption of some antibiotics.
7 (theoretically possible interference with drugs where gastric pH affects bioavailability; includes ampicillin esters)
Unsupported Statements
Paracetamol/acetaminophen and most non-prescription cold medicines usually have no major direct interaction with omeprazole because their absorption is not strongly dependent on stomach acidity.
No provided label support in the available sections for blanket exclusion of these drug classes/interactions.
Omeprazole is used in children to protect the stomach from acid-related irritation.
Provided label sections support pediatric GERD treatment/erosive esophagitis healing, but the specific generalized phrasing 'protect the stomach from acid-related irritation' is not explicitly stated in the provided label excerpts.
Omeprazole may be given alongside anti-inflammatory pain medicines (e.g., ibuprofen) used for aches, sprains, or fever.
No provided label support in the available sections for compatibility/interactions with ibuprofen or general NSAID co-administration.
No specific, widely cited child-drug interaction is typical with ibuprofen beyond general need to follow dosing and age guidance.
No provided label support for ibuprofen-specific (or 'widely cited') interaction statements.
Omeprazole may reduce symptoms related to acid when taken with other stomach-irritating medicines.
Not supported as a labeled interaction/safety statement in the provided sections.
Omeprazole does not remove the need to use other medicines only as directed.
Not supported as a labeled statement in the provided sections.
A prescriber may adjust timing or choose an alternative antibiotic when absorption may be reduced by omeprazole.
No provided label support for prescriber actions specifically described as timing adjustment or selecting alternatives.
Iron salts often need acid to dissolve better.
Mechanistic detail ('often need acid to dissolve better') is not supported by the provided label excerpts.
Timing separation may be advised for an iron supplement depending on the product and clinical need.
No provided label support for specific timing-separation advice with iron.
Antihistamines, cough syrups, and decongestants are not usually the main interaction concern with omeprazole.
No provided label support for these classes or for the 'not usually the main concern' framing.
The bigger issue with antihistamines, cough syrups, and decongestants is overlapping side effects ... rather than a direct drug-drug interaction with acid suppression.
No provided label support for this comparative claim about direct interactions vs overlapping adverse effects.
General best practice when drug interaction risk exists is to give omeprazole as directed.
Not supported as a specific labeling statement in the provided sections.
If the other medicine's label or clinician advises spacing, that spacing should be followed.
Not supported by provided labeling excerpts.
If combining multiple acid-dependent medicines (e.g., an antibiotic plus an iron supplement), a pharmacist should be asked whether to separate doses.
Not supported by provided labeling excerpts.
Contradictions
Important Omissions
Boxed warnings / contraindications / pregnancy and other key safety warnings (not evaluable because the provided claim set does not address them).
Importance:
High
Specific labeled drug-drug interaction monitoring requirements (e.g., warfarin INR/prothrombin time monitoring; CYP-metabolized drugs; atazanavir not recommended; tacrolimus interaction) were not addressed by the claims.
Importance:
High
Exact pediatric indication wording and age/limit statements (e.g., safety/effectiveness for GERD <1 year not established; other pediatric uses not established) were not addressed.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
While key acid-suppression and pH-dependent absorption concepts are supported, multiple interaction-management claims (timing separation, choice of antibiotic, class exclusions like OTC cold medicines/antihistamines) are not label-anchored in the provided sections, and important safety labeling elements (contraindications/boxed warnings and specific interaction monitoring guidance) are not covered by the claim set.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Several broad/speculative interaction and dosing-timing guidance statements are not supported by the provided FDA-label sections, and key safety-label areas are omitted.
Suggested Improvement
Constrain claims to label-supported points in the provided excerpts (acid suppression mechanism; theoretical pH-dependent absorption interference; explicitly listed interaction examples and monitoring; labeled administration instructions such as 'before eating' and swallowing whole). Remove or qualify unsupported OTC/ibuprofen/antihistamine/cough syrup/decongestant compatibility statements and avoid specific prescriber/pharmacist timing-separation recommendations unless explicitly present in the label sections provided.